ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
- PMID: 9176490
- DOI: 10.1038/nm0697-639
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Abstract
The 55-kilodalton (kDa) protein from the E1B-region of adenovirus binds to and inactivates the p53 gene, which is mutated in half of human cancers. We have previously shown that the replication and cytopathogenicity of an E1B, 55-kDa gene-attenuated adenovirus, ONYX-015, is blocked by functional p53 in RKO and U20S carcinoma lines. We now report that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5-9), were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or intravenous administration of ONYX-015 to nude mouse-human tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone.
Comment in
-
Progress of the smart bomb cancer virus.Nat Med. 1997 Jun;3(6):606-8. doi: 10.1038/nm0697-606. Nat Med. 1997. PMID: 9176482 No abstract available.
Similar articles
-
Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.Cancer Res. 2002 Feb 1;62(3):764-72. Cancer Res. 2002. PMID: 11830531
-
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.Clin Cancer Res. 2000 Dec;6(12):4908-14. Clin Cancer Res. 2000. PMID: 11156251
-
Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.Gene Ther. 2001 Mar;8(5):369-75. doi: 10.1038/sj.gt.3301402. Gene Ther. 2001. PMID: 11313813
-
Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015.Semin Cancer Biol. 2000 Dec;10(6):453-9. doi: 10.1006/scbi.2000.0336. Semin Cancer Biol. 2000. PMID: 11170867 Review.
-
Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?J Virol. 2001 Jun;75(12):5443-7. doi: 10.1128/JVI.75.12.5443-5447.2001. J Virol. 2001. PMID: 11356950 Free PMC article. Review. No abstract available.
Cited by
-
Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.J Virol. 2001 Apr;75(7):3474-9. doi: 10.1128/JVI.75.7.3474-3479.2001. J Virol. 2001. PMID: 11238874 Free PMC article.
-
Oncolytic viruses.Invest New Drugs. 1999;17(4):375-86. doi: 10.1023/a:1006334404767. Invest New Drugs. 1999. PMID: 10759404 Review.
-
Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33. doi: 10.2174/138920112800958850. Curr Pharm Biotechnol. 2012. PMID: 21740354 Free PMC article. Review.
-
Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo.J Exp Clin Cancer Res. 2009 Jun 15;28(1):81. doi: 10.1186/1756-9966-28-81. J Exp Clin Cancer Res. 2009. PMID: 19527508 Free PMC article.
-
Gene- and viral-based therapies for brain tumors.Neurotherapeutics. 2009 Jul;6(3):547-57. doi: 10.1016/j.nurt.2009.04.007. Neurotherapeutics. 2009. PMID: 19560744 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
